BACKGROUND: The combination of @entity136 and @entity900 has proven effective in the treatment of advanced @entity1149 ( @entity1149 ). However, the optimal schedule for administration of the two drugs has not yet been determined. In this study we evaluated the activity and @entity137 of a weekly @entity136 and @entity900 schedule. @entity1 AND METHODS: Thirty-six untreated @entity1 with stage IIIB IV @entity1149 entered the study. Treatment consisted of @entity136 1000 mg/m2 i.v. and @entity900 35 mg/m2 i.v., both given weekly on day 1,8, and 15, followed by one week of rest. RESULTS: Ninety-seven courses (273 weekly administrations) were delivered. The median dose-intensity was 612 mg/m2 per week for @entity136 (82%) and 21 mg/m2 per week for @entity900 (80%). All 36 of the @entity1 were evaluable for @entity137 , and 30 for response. Partial remissions were observed in 12 @entity1 , for an overall response rate of 40% (95% confidence interval (95% CI): 22.5%-57.5%). Most of the partial remissions were seen in IIIB @entity1 (54% of the stage IIIB and 22% of the stage IV @entity1 responded). According to the intent-to-treat principle, the response rate was 33.3% (12 of 36 @entity1 ). The median response duration was 9.9 months (range 4-23) and the median survival time 11.8 months (range 1-24). World Health Organization (WHO) grade 3-4 myelotoxicity was: @entity882 in nine @entity1 (25%), @entity1398 in six (16.6%) and @entity417 in six (16.6%); there was very little additional major @entity137 . CONCLUSIONS: This regimen appears to be active and to have a favourable @entity137 profile.

Weekly @entity136 and @entity900 in advanced XXXX : a phase II study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
